NCT04905810 - Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 9, 2022

Primary Completion Date

May 1, 2025

Study Completion Date

December 1, 2025

Conditions

Acute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Given IV

DRUG

Decitabine

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (4)

NOT_YET_RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

NOT_YET_RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

RECRUITING

UCSF-Fresno, Clovis

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento